Objective: Aberrant regulation of the synthesis and degradation of the extracellular matrix (ECM) is associated with the pathophysiology of vascular disease. Plasminogen activator inhibitor-1 (PAI-1) plays a crucial role in regulating the quantity and composition of ECM. However, regulatory mechanisms underlying the expression of the PAI-1 gene remain unclear. We examined the effects of all-trans-retinoic acid (atRA), either alone or in combination with mitogenic growth factor, basic fibroblast growth factor (bFGF), on the PAI-1 expression in cultured vascular smooth muscle cells (SMCs). Methods: Cultures of the rabbit vascular smooth muscle cell line C2 / 2 were used to study the effects of atRA and bFGF separately or together. Results: Treatment of vascular SMCs with atRA in combination with bFGF resulted in an additional increase in PAI-1 expression both at the mRNA and protein levels. In contrast, tissue-type plasminogen activator, urokinase-type plasminogen activator and tissue factor mRNA levels were only minimally affected. The all-trans-RA-and bFGF-mediated increases in PAI-1 mRNA levels were markedly attenuated by the tyrosine kinase inhibitor genistein, but not by MEK1 or p38MAP kinase inhibitors. The rate of decrease in PAI-1 mRNA levels after actinomycin D treatment was not affected by atRA and bFGF. Transient transfection of the PAI-1 promoter-luciferase reporter gene, which contains 967 bp of the 59-flanking region of the human PAI-1 gene, revealed that atRA and bFGF additionally increased transcription from this promoter. Progressive 59-deletion revealed that the promoter region required for such an effect lies between 2967 and 2260, which contains no canonical sequence for the RA-response element. In agreement with the role of PAI-1 in the inhibition of fibrinolytic activity which stimulates ECM degradation, cell migration was inhibited by treatment with atRA and bFGF. Conclusions: These results indicate that atRA and bFGF can function in a combined fashion and induce PAI-1 synthesis in vascular SMCs, and suggest a role for these two compounds in regulating SMC migration.
Introduction
minogen activator (uPA), and coagulation regulated by the specific plasminogen activator inhibitor PAI-1 and the Vascular smooth muscle cells (SMCs) play a critical role procoagulant protein tissue factor (TF) is important for in the progression of neointima formation after vascular degradation of ECM [6] . injury [1, 2] . A wealth of data demonstrates that the The fibrinolytic system comprises the inactive migration of SMCs, which is essential for neointima proenzyme plasminogen, which can be converted to the formation, requires degradation of extracellular matrix active enzyme plasmin, which induces the degradation of (ECM) components [3] [4] [5] . The balance between fibmany extracellular proteins either directly or through the rinolysis controlled by fibrinolytic enzymes, tissue-type activation of latent matrix metalloproteinases (MMPs) plasminogen activator (tPA) and urokinase-type plas- [7, 8] . The enzymatic action of tissue-type plasminogen activator (tPA) and of urokinase-type plasminogen activator (uPA), the two physiological plasminogen ac-tivators, is controlled by several plasminogen activator Recombinant human platelet-derived growth factor 32 inhibitors. Of these, plasminogen activator inhibitor-1 (PDGF) was provided by Calbiochem. [a-P]dCTP (3000 (PAI-1) is believed to be of primary importance [9] . Since Ci / mmol) was from Amersham. The stock solution of expression of the plasminogen system has also been atRA was prepared in ethanol, preserved at 2308C, and demonstrated in SMCs and leukocytes in human atherohandled in reduced light. sclerotic plaque [10] , normal as well as atherosclerotic or restenotic vessels are able to express the components of the 2.2. Cell culture and treatments plasminogen system required for controlled plasmin proteolysis after vascular injury.
C2 / 2 cells, an established cell line derived from rabbit Retinoids play a pivotal role in the development and aortic smooth muscle cell, were obtained from Life differentiation of diverse tissues [11, 12] . Retinoids exert Science Center, Biochemical Research Lab, Asahi Chemipleiotropic effects on a variety of cell types, including cal Industry [19] . Physiological and electromicroscopic vascular SMC in vitro [13, 14] . In addition, retinoids are studies have demonstrated that C2 / 2 cells conserve smooth able to reduce the intimal thickening induced by exmuscle phenotype [20] . Cells were grown in phenol redperimental injury in vivo [15] .
free DMEM supplemented with 10% heat-inactivated FCS, A large number of growth factors, cytokines and vaso-100 U / ml penicillin, 100 mg / ml streptomycin, and 2 regulatory molecules participate in the formation of the mmol / l L-glutamine. Cells were incubated at 378C and atherosclerotic lesions resulting from the excessive inequilibrated with 5% CO in humidified air. At confluence, 2 flammatory fibroproliferative response to various forms of the culture medium was changed to serum-free DMEM. insults to endothelial cells and SMC of the artery [16] .
Twenty-four hours later, atRA and / or bFGF were added at Among these is basic fibroblast growth factor (bFGF), a the specified concentrations. Control cells received ethanol peptide growth factor which plays a key role in mediating or dimethyl sulfoxide (DMSO) as a vehicle control, and cell proliferation, tissue differentiation, and tissue repair the final concentration of ethanol or DMSO in the medium [17] .
did not exceed 0.1%. When inhibitors were used, cells A recent study has suggested that the effect of retinoic were pretreated for 1 h with varying doses of inhibitors acids on cell proliferation is dependent on the growth before the addition of atRA and / or bFGF. At the indicated condition of the cells; retinoic acid stimulates DNA time, the cultures were lysed with Isogen (Nippon Gene) synthesis and cellular proliferation under conditions in and stored at 2808C until isolation of RNA, or superwhich growth factors are absent in culture, but it inhibits natants were harvested and stored at 2808C until assay of growth in the presence of growth factors [18] . The PAI-1 production. All our experiments were performed in molecular mechanisms behind these observations remain to serum-free medium to eliminate the possible modulatory be elucidated. The aim of the present study was to factor(s) contained in sera. investigate the effects of atRA and bFGF, two distinct vasoactive substances, on the fibrinolytic system in vascu-2.3. Isolation of RNA and Northern blot analysis lar SMCs. To achieve this, we used cultured vascular SMCs and examined gene expression of PAI-1, tPA, uPA, Total RNA was extracted from the cells using Isogen and TF. We further determined the molecular mechanism according to the manufacturer's procedure. Each RNA (15 underlying the combined effect of atRA and bFGF on mg) was denatured, subjected to electrophoresis through a PAI-1 gene expression.
1.2% agarose gel in the presence of formaldehyde and then transferred onto Biodyne nylon membranes (Pall BioSupport). The membranes were optimally cross-linked with 2. Methods UV light (Stratagene), and hybridized for 14 h at 428C with cDNA probes for either human PAI-1, tPA, uPA or 2.1. Materials TF. After hybridization, the filters were washed under conditions of high stringency in 23SSC containing 0.1% All-trans-retinoic acid (atRA), calphostin C, genistein, SDS. All filters were stripped and then sequentially and actinomycin D were purchased from Sigma. PD 98059 hybridized with a cDNA encoding glyceraldehyde 3-phosand tyrphostin A23 were obtained from BIOMOL Rephate dehydrogenase (GAPDH), which was used as a search Laboratories, and SB 203580, herbimycin A (RGloading control. The cDNA probes were obtained by 50810) were purchased from Calbiochem. All reagents polymerase chain reaction (PCR) as previously described 32 were used at the recommended concentrations to avoid cell [21] , and labeled with [a-P]dCTP using a random toxicity. Phenol red-free Dulbecco's modified Eagle's primed DNA labeling kit. Autoradiography was performed medium (DMEM), L-glutamine, fetal calf serum (FCS), using an intensifying screen and Kodak XAR5 (Eastman streptomycin, and penicillin were obtained from Gibco.
Kodak Company) film at 2808C for 3-7 days. The Basic fibroblast growth factor (bFGF) and a random hybridization signal was quantitated by densitometry, primer kit were obtained from Boehringer Mannheim.
normalized to that obtained with GAPDH.
Promoter-luciferase vector
for 12 h, the medium was replaced with serum starvation DMEM for 12 h and then cells were treated with atRA PAI-1-luciferase reporter gene vector containing an (0.32 mM) and / or bFGF (32 ng / ml). After 12 h, the cells approximate 3.4-kb DNA insert was kindly provided by were washed with PBS, and lysed in 120 ml of Cell Dr. Douglas E. Vaughan (Vanderbilt University Medical Culture Lysis Reagent (Promega). The luciferase activity Center, Nashville, TN, USA). Progressive deletions from of each cell lysate was measured using a Berthold Lumat the 59 end of the human PAI-1 gene promoter fragments LB9501 luminometer, and was normalized to the cellular were constructed by using PCR methods to create fragprotein concentration. The protein concentration of each ments of PAI-1 promoter into the pGL3-Basic luciferase sample was measured using a Bio-Rad DC protein assay vector (Promega) as previously described [21] . All fragsystem (Bio-Rad Laboratories). Each transfection was ments had an identical 39 end (i.e. the XhoI site at portion repeated at least three times in duplicate. 182) and 59 end (i.e. the KpnI site at each portion). The identity of all new constructs was confirmed by sequencing.
2.6. ELISA for PAI-1
Transient transfection and luciferase assay
The concentrations of PAI-1 produced were measured using a commercially available ELISA kit (American For transient transfection experiments, C2 / 2 cells were Diagnostica) as stated in the figure legends. The culture cultured in 35-mm dishes using phenol red-free DMEM supernatants were collected after stimulation for 24 h and supplemented with 10% FCS. When cells reached 60% the absorbance was measured at 450 nm. PAI-1 production confluence, they were transfected using Tfx-50 (Promega), was normalized to the volume of the medium and cell with 1 mg of the PAI-1 pGL3 constructs. After incubation number. To investigate the modulation of PAI-1 gene expression containing the chemoattractant PDGF-BB (10 ng / ml).
by atRA and / or bFGF, C2 / 2 cells were incubated in fresh After 24 h incubation, non-migratory cells on the upper serum-free medium 24 h before the addition of increasing surface were removed with cotton swabs. The chamber concentrations of either atRA or bFGF. The effects of membranes were stained with crystal violet staining solueither atRA or bFGF on PAI-1 gene expression were tion. Stained migratory cells were solubilized with exdose-dependent with maximal stimulation occurring at traction buffer and the absorbance was measured at 570 concentrations of 0.32 mM and 32 ng / ml, respectively nm. The number of migratory cells appearing on the (Fig. 1A ). Higher doses of atRA (0.64 mM) or bFGF (64 underside of the chamber was expressed as absorbance. ng / ml) did not induce a further expression of PAI-1 mRNA. However, simultaneous stimulation with atRA and bFGF further potentiated PAI-1 mRNA levels even after 2.8. Statistical analysis each ligand alone induced a maximum expression of PAI-1 mRNA (Fig. 1A) . In contrast, tPA, uPA and TF mRNA Results are presented as the mean6standard error of the levels were not altered by treatment with atRA alone or in mean (S.E.M.) for at least three separate experiments.
combination with bFGF (data not shown). As shown in Analysis of variance (ANOVA) was used to analyze the Fig. 1B , the combined effect of atRA and bFGF was time-dependent. All-trans-RA action on PAI-1 mRNA homology motifs, which confer a narrower range of action levels was detected as early as 2 h after treatment. The [23] , had no effect on this induction. Tyrphostin A23, enhancement reached a maximum after 4 h of treatment which potently inhibits the epidermal growth factor (EGF) and was followed by a decrease to basal levels at 24 h. receptor tyrosine kinases [24] , increased basal levels of bFGF-induced enhancement of PAI-1 mRNA levels PAI-1 mRNA. Our data support the involvement of reached a peak after 2 h and declined thereafter.
genistein-sensitive tyrosine kinases in atRA / bFGF-induced PAI-1 expression. We also observed that genistein blocked 3.2. Combined effect of atRA and bFGF on PAI-1 the inducible expression of the PAI-1 gene by either atRA mRNA expression was mediated through a tyrosine or bFGF alone (Fig. 3) . To assess whether the observed kinase-dependent pathway reduction in PAI-1 mRNA levels was due to a non-specific inhibition of mRNA or unequal RNA application, the blots To investigate the intracellular mechanisms involved in were also probed with a GAPDH cDNA probe. GAPDH the combined induction of the PAI-1 gene, C2 / 2 cells were mRNA levels did not change under any experimental treated for 1 h with each of the various inhibitors of condition. intracellular signaling pathways before the addition of atRA and / or bFGF. First, we investigated whether MAP 3.3. All-trans-RA-and bFGF-induced PAI-1 mRNA kinases are important mediators for the effects of atRA and expression at the transcriptional levels bFGF on the PAI-1 gene expression in C2 / 2 cells. Fig. 2A shows that inhibition of ERKs and p38 MAPK signaling
To determine whether simultaneous stimulation with with PD98059 and SB203580, respectively, had no effects atRA and bFGF increases steady-state levels of PAI-1 on the atRA-and bFGF-induced PAI-1 mRNA expression.
mRNA at the transcriptional levels or at post-transcriptionCalphostin C, a specific inhibitor of PKC, had no effects al levels, the measurement of the PAI-1 mRNA half-life either. In contrast, genistein (50 mM), which competes at was performed in the presence or absence of atRA and the ATP-binding site and thus has a broad range of action bFGF. C2 / 2 cells were stimulated for 4 h with a combina- [22] , blocked atRA / bFGF-stimulated PAI-1 mRNA extion of 0.32 mM atRA and 32 ng / ml bFGF, then each pression, whereas herbimycin A, which binds to Srcmedium was changed and actinomycin D (5 mg/ml) was added with or without atRA / bFGF. The incubations were These results indicate that the major sequence determinants continued for the next 6 h. The rate of decrease in PAI-1 of combined responsiveness in the PAI-1 promoter reside mRNA levels after actinomycin D treatment was not between 2967 and 2260, where no RA-response element affected by atRA / bFGF (Fig. 4) . Thus, simultaneous (RARE)-like sequence was present. stimulation with atRA and bFGF has no effect on the stability of PAI-1 mRNA, suggesting that the observed 3.5. Regulation of PAI-1 production by atRA and /or increase in PAI-1 mRNA levels by atRA / bFGF was due to bFGF an increase in transcription from the PAI-1 promoter. The half-life of the PAI-1 mRNA was not affected by either
To assess whether the observed increase represents upatRA or bFGF alone (data not shown).
regulation in PAI-1 production, specific ELISA was performed. Confluent cultures of C2 / 2 cells were serum 3.4. All-trans-RA and bFGF increased PAI-1 promoter starved for 24 h and then incubated with fresh serum-free activity medium containing atRA (0.32 mM) and bFGF (32 ng / ml) individually or together for 24 h. Culture medium was Next, we performed a transient transfection assay to harvested and the PAI-1 production was assayed. As determine the promoter region mediating the effects of the shown in Fig. 6A , PAI-1 production was significantly atRA and bFGF on PAI-1 transcription. C2 / 2 cells were stimulated by bFGF alone. All-trans-RA alone had a small transiently transfected with 2967Luc, and the luciferase effect on PAI-1 production. Consistent with the effects activity was measured 12 h after stimulation with atRA observed at the level of PAI-1 mRNA, a combined increase and bFGF individually or together. As shown in Fig. 5 , the in PAI-1 production was observed when atRA was applied increase in the luciferase activity of 2967Luc was comin combination with bFGF. parable between stimulation of atRA and bFGF (two-fold increase). Co-treatment with atRA and bFGF resulted in a 3.6. Effects of atRA and /or bFGF on C2 /2 migration higher luciferase activity (four-fold). Deletion of the 59-flanking region to 2260Luc eliminated such a response.
To investigate the effect of atRA and / or bFGF on cell involvement of these kinases in RA-mediated gene expression. Thus, the findings of combined activation of the PAI-1 gene by atRA and bFGF offer a novel insight into the mechanisms of the genetic response of vascular SMC to two distinct vasoactive substances, atRA and bFGF. There are several previous reports suggesting that tyrosine kinase is involved in the regulation of gene expression by atRA [26, 27] . Shang et al. demonstrated that atRA exerts IFN-like actions by phosphorylating the signal transducer and activator of transcription 1 (STAT1) in breast carcinoma cell line MCF-7 [28] . Thus it is intriguing to speculate that atRA increases PAI-1 promoter activity through inducing phosphorylation of STAT1. However, this seems unlikely because our Western blot analysis revealed that atRA treatment did not induce phosphorylation of STAT1 (data not shown). Investigation of the tyrosine kinases responsible for the increased phorylated by MAPK, results in activation of the estrogen *P , 0.05 compared with control cells (n 5 6). **P , 0.05 compared receptor as a transcription factor [30] . Alternatively, it is with values in atRA and bFGF-treated cells (n 5 6). also possible that atRA-mediated signaling increases the activity of the bFGF receptor. This mechanism is analomigration, we performed a migration assay. The number of gous to that in a recent study by Yen et al. [31] . They C2 / 2 migrating across the membrane was dependent on demonstrated that RA induces myeloid differentiation of the presence of a chemoattractant, PDGF-BB. As shown in HL-60 cells by activating the signal transduction cascade Fig. 6B , treatment with atRA and / or bFGF reduced the originating from c-FMS, a transmembrane tyrosine kinase cell migration elicited by PDGF-BB regardless of the receptor of the PDGF subfamily. In addition, we cannot membrane coating (percent inhibition in the average of the rule out the possibility that atRA-and bFGF-mediated results using the BSA and collagen I-coated membrane:
signalings interact with each other at post-receptor levels. 74, 70 and 63% by atRA, bFGF and the combination, Results of the transient transfection assays and standard respectively).
decay assays using actinomycin D indicate that such a combined effect between atRA and bFGF is mainly regulated at the transcriptional levels. Searching for the putative regulatory sequence mediating bFGF-induced 4. Discussion PAI-1 promoter activity revealed that AP1-and SP1-binding sites are in the promoter region between 2967 and In this study, we report the novel observation that atRA 2260. We observed that PAI-1 gene expression is induced alone or in combination with bFGF stimulates the proby RARa overexpression (unpublished data) as well as by duction of PAI-1 from vascular SMCs at both the protein atRA, suggesting that atRA-induced PAI-1 gene transcripand mRNA levels. Furthermore, atRA and bFGF sigtion is an RAR-mediated effect. Despite the report that nificantly decreased SMC migration. Our data suggest that RA-induced signaling is mainly mediated through the atRA and bFGF induced PAI-1 mRNA in a gene-specific binding of RAR receptor to its cognate binding sequence manner, since these ligands did not alter tPA nor uPA in the promoter region [32] , no canonical RARE is found mRNA levels. In addition, the induction of PAI-1 was in the RARa-responsive region. These results suggest that inhibited by the tyrosine kinase inhibitor genistein, thus RARa exerts its role by modulating DNA-binding transuggesting that the tyrosine kinase-dependent step is scription factors through direct or indirect protein-protein involved in the regulation of PAI-1 gene expression by interaction. Further studies will obviously be required to atRA and bFGF. Although numerous studies have docuunderstand the precise mechanism responsible for the mented that tyrosine kinases play a crucial role in mediatatRA-induced transcription of the PAI-1 gene. ing the effect of bFGF [25] , few reports have described the The finding that bFGF inhibits the migration of C2 / 2 cells in our migration assay system was surprising because demonstrate that tyrosine kinase(s) is involved in the a number of studies demonstrated that bFGF stimulates induction of PAI-1 triggered by atRA and bFGF. Although SMC migration [33, 34] . However, given that the activation the functional sequelae of the augmented expression of the of fibrinolytic enzymes is a prerequisite for SMC migration PAI-1 gene by atRA and bFGF in vascular SMCs in [3] [4] [5] , our results would be reconciled by the fact that, in relation to neointima formation appear to be quite com-C2 / 2 cells, bFGF did not induce expression of the tPA and plex, SMC migration is actually inhibited by treatment uPA genes, which may play a critical role in activating the with atRA and bFGF in our system. The secretion of PAI-1 metalloproteinase system and in degrading ECM. The could have the effects of both down-regulating plasminability of cells to express tPA and uPA in response to bFGF mediated ECM degradation and down-regulating MMPs may be different among cellular types, because Miralles et activation [36] , and may contribute substantially to the al. have shown that the uPA gene is regulated by bFGF decrease in vascular SMC migration. At the site of the differently in myoblasts from myotubes [35] . Thus, our neointima, a growth factor such as bFGF is produced results suggest that the action of bFGF on migration abundantly by vascular SMCs [37] and induces PAI-1 largely depends upon the cellular properties which deproduction. All-trans-RA treatment may augment this antitermine the pattern of fibrinolysis-relevant genes expressed proteolytic state of vascular SMCs by increasing the in response to bFGF. synthesis and secretion of PAI-1, thereby further decreasIn summary, the present study illustrates that atRA and ing the migration rate. The fact that atRA interacts with bFGF induce PAI-1 gene expression, the principal inhibbFGF may provide the basis for the pleiotropic effects of itory factors of the fibrinolytic system, without affecting atRA and a rationale for the use of retinoids as therapeutic tPA or uPA expression in vascular SMCs. Furthermore, we agents to induce PAI-1 in the vessel wall.
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